Anti-NMDA Receptor Encephalitis clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for Anti-NMDA Receptor Encephalitis research studies include Jeffrey Gelfand.
Last updated: